Navigation Links
Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
Date:10/7/2009

CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 17th Annual BioPartnering Europe conference in London, U.K. on Monday, October 12 at 10:15 a.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 11-13, 2009.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
2. Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America
3. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
4. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
5. Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
6. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
7. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
8. Bio-enabled, surface-mediated approach produces nanoparticle composites
9. avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
10. Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit
11. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... MS Technologies™ and Bayer have ... Soybean Performance System will combine industry-leading genetics with a double herbicide-tolerant trait that ... Balance® Bean herbicide. The Balance™ GT Soybean Performance System will benefit soybean growers ...
(Date:1/17/2017)... 2017 The Global Implantable Biomaterials Market ... around 7.5% over the next decade to reach ... prominent trends that the market is witnessing include ... graft transplant surgeries and medical implants and technological ... categorized into immunomodulatory biomaterials, natural, polymers, hydrogels and ...
(Date:1/17/2017)...  An international team of researchers from UC ... Hospital Albrechtsen Research Centre/University of Manitoba have identified ... need affecting nearly one in 15 Americans. Published ... results identify small molecule drugs with neuroprotective and ... in animal models of metabolic, chemical and infection ...
(Date:1/17/2017)... N.J. , Jan. 17, 2017 Roka Bioscience, Inc. ... providing advanced testing solutions for the detection of foodborne pathogens today ... CEO.  Ms. Duseau succeeds Paul Thomas , the Company,s President ... of the Company,s Board of Directors.  The changes are effective today. ... of Directors, effective today. ...
Breaking Biology Technology:
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
Breaking Biology News(10 mins):